The role of lymphatic transport in enhancing oral protein and peptide drug delivery

Drug Development and Industrial Pharmacy

Volumn 28, Issue 9, 2002, Pages 1047-1058

  Wasan, Kishor M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Lipid absorption; Lymphatic drug transport; Peptide like drugs; Protein like drugs

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CALCITONIN; CYCLOSPORIN; EMULSIFYING AGENT; ENKEPHALIN; HALOFANTRINE; IMMUNOMODULATING AGENT; INSULIN; LEUKOTRIENE B4 RECEPTOR ANTAGONIST; LIPID; MEPITIOSTANE; MICROSPHERE; MILK FAT; NAFTIFINE; OLIVE OIL; ONTAZOLAST; PEPTIDE DERIVATIVE; PHOSPHATIDYLCHOLINE; POLYCHLORINATED BIPHENYL; PROBUCOL; PROTEIN DERIVATIVE; PROTIRELIN; SOYBEAN OIL; TESTOSTERONE UNDECANOATE; TETRAGASTRIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNSATURATED FATTY ACID; VALSPODAR; VITAMIN; DRUG; PEPTIDE; PROTEIN;

CANCER CELL; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXPOSURE; DRUG TRANSPORT; EMULSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID ABSORPTION; LIPID METABOLISM; LIPID TRANSPORT; LYMPHATIC SYSTEM; METASTASIS; NONHUMAN; REVIEW; SYSTEMIC CIRCULATION; ANIMAL; DIGESTIVE SYSTEM; DRUG DELIVERY SYSTEM; INTESTINE ABSORPTION; METABOLISM; ORAL DRUG ADMINISTRATION; SOLUBILITY; TRANSPORT AT THE CELLULAR LEVEL;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL TRANSPORT; DIGESTIVE SYSTEM; DRUG DELIVERY SYSTEMS; HUMANS; INTESTINAL ABSORPTION; LIPID METABOLISM; LIPIDS; LYMPHATIC SYSTEM; PEPTIDES; PHARMACEUTICAL PREPARATIONS; PROTEINS; SOLUBILITY;

EID: 0036411713     PISSN: 03639045     EISSN: None     Source Type: Journal    
DOI: 10.1081/DDC-120014573     Document Type: Review

References (72)

1. Pouton, C.W.; Charman, W.N. The potential of oily formulations for drug delivery to the gastrointestinal tract. Adv. Drug Del. Rev. 1997, 25, 1-2.
2. Porter, C.J.H.; Charman, W.N. Uptake of drugs into the intestinal lymphatics after oral administration. Adv. Drug Del. Rev. 1997, 25, 71-89.
3. Serajuddin, A.T.M.; Sheen, P.C.; Mufson, D.; Berstein, D.F.; Augustine, M.A. Effect of vehicle amphiphilicity on the dissolution and bioavailability of a poorly water-soluble drug from solid dispersions. J. Pharm. Sci. 1988, 77, 414-417.
4. Sheen, P.C.; Kim, E.I.; Petillo, J.J.; Serajuddin, A.T.M. Bioavailability of a poorly water-soluble drug from tablet and solid dispersion in humans. J. Pharm. Sci. 1991, 80, 712-714.
5. Hofmann, A.F.; Borgstrom, B. Physico-chemical state of lipids in intestinal content during their digestion and absorption. Feb. Proc. 1986, 21, 43-50.
6. Shiau, Y.-F. Mechanism of intestinal fat absorption. Am. J. Physiol. 1981, 240, G1-G9.
7. Borgstrom, B.; Dahlqvist, A.; Lundh, G.; Sjovall, J. Studies of intestinal digestion and absorption in the human. J. Clin. Invest. 1957, 36, 1121-1136.
8. Ueda, C.T.; Lemaire, M.; Gsell, G.; Nussbaumer, K. Intestinal lymphatic absorption of cyclosporin a following oral administration in an olive oil solution to rats. Biopharm. Drug Dispos. 1983, 4, 113-124.
9. Reymond, J.P.; Sucker, H.; Vonderscher, J. In vivo model for ciclosporin intestinal absorption in lipid vehicles. Pharm. Res. 1988, 5, 677-679.
10. Thomson, A.B.R.; Keelan, M.; Garg, M.L.; Clandinin, M.T. Intestinal aspects of lipid absorption: In review. Can. J. Physiol. Pharmacol. 1989, 67, 179-191.
11. Charman, W.N.; Porter, C.J.H. Lipophilic prodrugs designed for intestinal lymphatic transport. Adv. Drug Del. Rev. 1996, 19, 149-169.
12. Tucker, G. Drug delivery: Lymphing along? Lancet 1993, 341, 1314-1315.
13. Carey, M.C.; Small, D.M.; Bliss, C.M. Lipid digestion and absorption. Ann. Rev. Physiol. 1983, 45, 651-677.
14. Thomson, A.B.; Schoeller, C.; Keelan, M.; Smith, L.; Clandinin, M.T. Lipid absorption: Passing through the unstirred layers, brush border membrane, and beyond. Can. J. Physiol. Pharmacol. 1993, 71, 531-555.
15. Tso, P., Simmonds, W.J. The absorption of lipid and lipoprotein synthesis. Lab. Res. Meth. Biol. Med. 1984, 10, 191-216.
16. Tso, P.; Balint, J.A. Formation and transport of chylomicrons by enterocytes to the lymphatics. Am. J. Physiol. 1986, 13, G715-G726.
17. Tso, P. Intestinal lipid absorption. In Physiology of the Gastrointestinal Tract; Johnson, L.R., Ed.; Raven Press: New York, 1994; 1867-1908.
18. Davis, R.A.; Vance, J.E. Structure, assembly and secretion of lipoproteins. In Biochemistry of Lipids, Lipoproteins and Membranes; Vance, D.E., Vance, J.E., Eds.; Elsevier: New York, 1996; 473-493.
19. Repa, J.J.; Turley, S.D.; Lobaccaro, J.M.A.; Medina, J.; Li, L.; Lustig, K.; Shan, B.; Heyman, R.A.; Dietschy, M.; Mangelsdorf, D.J. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 2000, 289, 1524-1529.
20. Mueller, J.H. The mechanism of cholesterol absorption. J. Biol. Chem. 1916, 27, 463-480.
21. Wilson, M.D.; Rudel, L.L. Review of cholesterol absorption with emphasis on dietary and biliary cholesterol. J. Lipid Res. 1994, 35, 943-955.
22. Biggs, M.W.; Friedman, M.; Byers, S.O. Intestinal lymphatic transport of absorbed cholesterol. Proc. Soc. Exp. Biol. Med. 1951, 78, 641-643.
23. 14. J. Biol. Chem. 1952, 194, 407-412.
24. Rudel, L.L.; Morris, M.D.; Felts, J.M. The transport of exogenous cholesterol in the rabbit. I. Role of cholesterol ester of lymph chylomicra and lymph very low density lipoproteins in absorption. J. Clin. Invest. 1972, 51, 2686-2692.
25. Hellman, L.; Frazell, E.L.; Rosenfeld, R.S. Direct measurement of cholesterol absorption via the thoracic duct in man. J. Clin. Invest. 1960, 39, 1288-1294.
26. Davidson, N.O. Cellular and molecular mechanisms of small intestinal lipid transport. In Physiology of the Gastrointestinal Tract; Johnson, L.R., Ed.; Raven Press: New York, 1994; 1909-1934.
27. Johnson, J.M. Triglyceride biosynthesis in the intestinal mucosa. In Lipid Absorption: Biochemical and Clinical Aspects; Rommel, K., Goebell, H., Bohmer, R., Eds.; MTP Press: Lancaster, 1976; 85-94.
28. Zilversmit, D.B. The composition and structure of lymph chylomicrons in dog, rat and man. J. Clin. Invest. 1965, 44, 1610-1622.
29. McDonald, G.B.; Weidman, M. Partitioning of polar fatty acids into lymph and portal vein after intestinal absorption in the rat. Q. J. Exp. Physiol. 1987, 72, 153-159.
30. Deak, S.T.; Csaky, T.Z. Factors regulating the exchange of nutrients and drugs between lymph and blood in the small intestine. Microcirc. Endothel. Lymph. 1984, 1 (5), 569-588.
31. 2-α-tocopheryl nicotinate in the rat. Int. J. Vitam. Nutr. Res. 1970, 40, 505-514.
32. Ikeda, I.; Imasato, Y.; Sasaki, E.; Sugano, M. Lymphatic Transport of alpha-, gamma- and delta-tocotrienols and alpha-tocopherol in rats. Int. J. Vitam. Nutr. Res. 1996, 66, 217-221.
33. Muranishi, S. Delivery system design for improvement of intestinal absorption of peptide drugs. Yakugaku Zasshi 1997, 117, 394-414.
34. Yanagawa, A.; Iwayama, T.; Saotome, T.; Shoji, Y.; Takano, K.; Oka, H.; Nakagawa, T.; Mizushima, Y. Selective transfer of cyclosporin to thoracic lymphatic systems by the application of lipid microspheres. J. Microencaps. 1989, 6, 161-164.
35. Sato, H.; Liu, H.X.; Adachi, I.; Ueno, M.; Lemaire, M.; Horikoshi, I. Enhancement of the intestinal absorption of a cyclosporine derivative by milk fat globule membrane. Biol. Pharm. Bull. 1994, 17, 1526-1528.
36. Horst, H.J.; Holte, W.J.; Dennis, M.; Coert, A.; Geelen, J.; Voigt, K.D. Lymphatic absorption and metabolism of orally administered testosterone undecanoate in man. Klin. Wschr. 1976, 54, 875-879.
37. Sugihara, J.; Furuuchi, S.; Ando, H.; Takashima, K.; Harigaya, S. Studies on the intestinal lymphatic absorption of drugs. II. Glyceride prodrugs for improving the lymphatic absorption of naproxen and nicotinic acid. J. Pharmacobio-Dyn. 1988, 11, 555-562.
38. Sugihara, J.; Furuuchi, S. Lymphatic absorption of hypolipidemic compound 1-O-[p-(myristyloxy)-α-methylcinnamoyl]glycerol (LK-903). J. Pharmacobio-Dyn. 1988, 11, 121-130.
39. Adachi, I.; Liu, H.; Horkoshi, I.; Ueno, M. Possibility of lymphatic absorption of epidermal growth factor from intestine. Yakugaku Zasshi 1993, 113, 256-263.
40. Hauss, D.J.; Mehta, S.; Radebaugh, G.W. Targeted lymphatic transport and modified systemic distribution of CI-976, a lipophilic lipid-regulator drug, via a formulation approach. Int. J. Pharm. 1994, 108, 85-93.
41. Barnwell, S.G.; Laudanski, T.; Story, M.J.; Mallinson, C.B.; Harris, R.J.; Cole, S.K.; Keating, M.; Attwood, D. Improved oral bioavailability of propranolol in healthy human volunteers using a liver bypass drug delivery system containing oleic acid. Int. J. Pharm. 1992, 88, 423-432.
42. Grimus, R.C.; Schuster, I. The role of the lymphatic transport in the enteral absorption of naftifine by the rat. Xenobiotica 1984, 14, 287-294.
43. Palin, K.J.; Wilson, C.J. The effect of different oils on the absorption of probucol in the rat. J. Pharm. Pharmacol. 1984, 36, 641-643.
44. Ichihashi, T.; Kinoshita, H.; Shimamura, K.; Yamada, H. Absorption and disposition of epithiosteroids in rats (1): Route of administration and plasma levels of epitiostanol. Xenobiotica 1991, 21, 865-872.
45. Ichihashi, T.; Kinoshita, H.; Yamada, H. Absorption and disposition of epithiosteroids in rats (2): Avoidance of first-pass metabolism of mepitiostane by lymphatic absorption. Xenobiotica 1991, 21, 873-880.
46. Ichihashi, T.; Kinoshita, H.; Takagishi, Y.; Yamada, H. Effect of oily vehicles on absorption of mepitiostane by the lymphatic system in rats. J. Pharm. Pharmacol. 1992, 44, 560-564.
47. Ichihashi, T.; Kinoshita, H.; Takagishi, Y.; Yamada, H. Effect of bile on absorption of mepitiostane by the lymphatic system in rats. J. Pharm. Pharmacol. 1992, 44, 566-569.
48. Ichihashi, T.; Kinoshita, H.; Takagishi, Y.; Yamada, H. Intrinsic lymphatic partition rate of mepitiostane, epitiostanol and oleic acid absorbed from rat intestine. Pharm. Res. 1991, 8, 1302-1306.
49. Porter, C.J.H.; Charman, S.A.; Charman, W.N. Lymphatic Transport of Halofantrine in the Triple-Cannulated Anaesthetized Rat Model: Effect of Lipid Vehicle Dispersion. J. Pharm. Sci. 1996, 85, 351-356.
50. Humberstone, A.J.; Porter, C.J.H.; Charman, W.N. A physicochemical basis for the effect of food on the absolute bioavailability of halofantrine. J. Pharm. Sci. 1996, 85, 525-529.
51. Wasan, K.M.; Ramaswamy, M.; MacIntosh, M.; Porter, C.J.H.; Charman, W.N. Differences in the lipoprotein distribution of halofantrine are regulated by lipoprotein apolar lipid and protein concentration and lipid transfer protein I activity: In vitro studies in normolipidemic and dyslipidemic human plasmas. J. Pharm. Sci. 1999, 88, 185-190.
52. Busbee, D.L.; Yoo, J.-S.H.; Norman, J.O.; Joe, C.O. Polychlorinated biphenyl uptake and transport by lymph and plasma components. Proc. Soc. Exp. Biol. Med. 1985, 179, 116-122.
53. 4 inhibitor. J. Pharm. Sci. 1998, 87, 165-169.
54. Caliph, S.M.; Charman, W.N.; Porter, C.J. Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats. J. Pharm. Sci. 2000, 89, 1073-1084.
55. Hauss, D.J.; Fogal, S.E.; Ficorilli, J.V. Chronic collection of mesenteric lymph from conscious, tethered rats. Contemp. Top. Lab. Anim. Sci. 1998, 37, 56-58.
56. White, D.G.; Story, M.J.; Barnwell, S.G. An experimental animal model for studying the effects of a novel lymphatic drug delivery system for propranolol. Int. J. Pharm. 1991, 69, 169-174.
57. Kararli, T.T. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm. Drug Dispos. 1995, 16, 351-380.
58. Levet-Trafit, B.; Gruyer, M.S.; Marjanovic, M.; Chou, R.C. Estimation of oral drug absorption in man based on intestine permeability in rats. Life Sci. 1996, 58, PL359-363.
59. Liu, H.-X.; Adachi, I.; Horkoshi, I.; Ueno, M. Mechanism of promotion of lymphatic drug absorption by milk fat globule membrane. Int. J. Pharm. 1995, 118, 55-64.
60. Chang, C.M.; Bodmeier, R. Binding of drugs to monoglyceride-based drug delivery systems. Int. J. Pharm. 1997, 147, 135-142.
61. Shah, N.H.; Carvajal, M.T.; Patel, C.I.; Infeld, M.H.; Malick, A.W. Self-emulsifying drug delivery systems (SEDDS) with polyglycolyzed glycerides for improving in vitro dissolution and oral absorption of lipophilic drugs. Int. J. Pharm. 1994, 106, 15-23.
62. Fagerholm, U.; Johansson, M.; Lennernas, H. Comparison between permeability coefficients in rat and human jejunum. Pharm. Res. 1996, 13, 1336-1342.
63. Soria, I.; Zimmerman, C.L. The validation of the intestinal permeability approach to predict oral fraction of dose absorbed in humans and rats. Biopharm. Drug Dispos. 1996, 17, 817-818.
64. Pahl, M.V.; Oveisi, F.; Khamiseh, G.; Vaziri, N.D. Intestinal absorption and biliary secretion of cholesterol in rats with nephrotic syndrome. Nephr., Dial., Transpl. 1998, 13, 1446-1451.
65. McDonald, G.B.; Saunders, D.R.; Weidman, M.; Fisher, L. Portal venous transport of long-chain fatty acids absorbed from rat intestine. Am. J. Physiol. 1980, 239, G141-G150.
66. Bugaut, M.; Carlier, H. Role of intestinal hydrolases, endogenous substrates and chyloportal partition in fat absorption. In Fat Absorption; Kuksis, A., Ed.; CRC Press: Boca Raton, FL, 1987; Vol. 1, 197-232.
67. Simmonds, W.J. The role of micellar solubilisation in lipid absorption. Aust. J. Exp. Biol. Med. Sci. 1972, 50, 403-421.
68. Muranishi, S. Drug targeting towards the lymphatics. Adv. Drug Del. Res. 1991, 21, 1-38.
69. Charman, W.N.; Stella, V.J. Estimating the maximal potential for intestinal lymphatic transport of lipophilic drug molecules. Int. J. Pharm. 1986, 34, 175-178.
70. Bollman, J.L.; Cava, J.C.; Grindley, J.H. Techniques for the collection of lymph from the liver, small intestine and thoracic duct of the rat. J. Lab. Clin. Med. 1948, 33, 1349-1352.
71. Reininger, E.J.; Saperstein, L.A. Effect of digestion on the distribution of blood flow in the rat. Science 1957, 126, 1176.
72. Sieber, S.M. The lymphatic absorption of p,p-DDT and some structurally-related compounds in the rat. Pharmacology 1976, 14, 443-454.